Skip to main content
PMC home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2010 Aug;71(4):211–238. doi: 10.1016/j.curtheres.2010.08.003

Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Wei-Xin Li 1,2, Jian-Feng Gou 3, Jin-Hui Tian 2, Xiang Yan 1,2,*, Lin Yang 1
PMCID: PMC3969618  PMID: 24688145

Abstract

Background: Glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of hypoglycemic drugs, including exenatide, liraglutide, albiglutide, lixisenatide, and taspoglutide. Insulin glargine is a standard agent used to supplement basal insulin in type 2 diabetes mellitus (T2DM).

Objective: The aim of this study was to review the efficacy and safety profiles of GLP-1 receptor agonists versus insulin glargine in type 2 diabetic patients who have not achieved treatment goals with oral hypoglycemic agents.

Methods: The Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expanded, and the database of ongoing trials were searched from inception through April 2010. Additional data were sought from relevant Web sites, the American Diabetes Association, reference lists of included trials and related (systematic) reviews, and industry. Randomized controlled trials (RCTs) were selected if they were ≥3 months in duration, compared GLP-1 receptor agonists with insulin glargine in patients with T2DM, and included ≥1 of the following outcomes: mortality, complications of T2DM, glycemie control, weight, lipids, blood pressure, adverse effects, and health-related quality of life. Quasirandomized controlled trials were excluded. The quality of the eligible studies was assessed on the basis of the following aspects: randomization procedure, allocation concealment, blinding, incomplete outcome data (intent-to-treat [ITT] analysis), selective outcome reporting, and publication bias.

Results: A total of 410 citations were retrieved; 5 multicenter RCTs that met the inclusion criteria were identified. They were all open-label designs with an insulin glargine arm, predefined outcomes reported, and ITT analysis. One trial had an unclear randomization procedure and allocation concealment. Publication bias was not able to be determined. No data wete found with regard to mortality or diabetes-associated complications, and few data were found on quality of life. The results of the metaanalysis suggest that insulin glargine was significantly better in reducing the fasting blood glucose (mean difference [MD] [95% CI], 1.31 [1.04 to 1.58]; P < 0.001), but exhibits greater incidence of nocturnal hypoglycemia (risk ratio [RR] [95% CI], 0.40 [0.23 to 0.71]; P = 0.002) and influenza (RR [95% CI], 0.56 [0.32 to 0.98]; P = 0.04). GLP-1 receptor agonists are more conducive to reducing weight (MD [95% CI], −3.96 [−5.14 to -2.77]; P < 0.001), postprandial blood glucose (after breakfast, P < 0.001; after dinner, P < 0.001), and LDL-C (MD [95% CI], −0.18 [−0.28 to −0.08]; P < 0.001), but have significantly more gastrointestinal adverse effects (eg, nausea/ vomiting, P < 0.001). There were no significant differences between GLP-1 receptor agonists and insulin glargine in reducing glycosylated hemoglobin (HbA1c) levels (MD [95% CI], −0.03 [−0.13 to 0.08]) and the overall incidence of hypoglycemia (RR [95% CI], 0.69 [0.42 to 1.14]).

Conclusions: Compared with insulin glargine, GLP-1 receptor agonists did not have a significant difference in regard to reducing HbA1c levels and they were significantly associated with decreased weight but increased gastrointestinal adverse events. It remains unclear whether GLP-1 receptor agonists influence mortality or diabetes-associated complications in patients with T2DM. More trials with longer follow-up are needed to determine the exact long-term efficacy and safety profiles of this new class of hypoglycemic drugs.

Key words: type 2 diabetes, diabetes mellitus, GLP-1, glucagon-like peptide-1, insulin glargine, insulin detemir, meta-analysis

Full Text

The Full Text of this article is available as a PDF (1.4 MB).

References

  • 1.Wild S, Roglic G, Green A. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053. doi: 10.2337/diacare.27.5.1047. [DOI] [PubMed] [Google Scholar]
  • 2.Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46:3–19. doi: 10.1007/s00125-002-1009-0. [DOI] [PubMed] [Google Scholar]
  • 3.Scheen AJ. Antidiabetic agents in subjects with mild dysglycaemia: Prevention or early treatment of type 2 diabetes? Diabetes Metab. 2007;33:3–12. doi: 10.1016/j.diabet.2006.11.005. [DOI] [PubMed] [Google Scholar]
  • 4.UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16 Overview of 6 years' therapy of type II diabetes: A progressive disease [published correction appeats in Diabetes. 1996;45:1655] Diabetes. 1995;44:1249–1258. [PubMed] [Google Scholar]
  • 5.Tutner RC, Cull CA, Frighi V, Holman RR, UK Prospective Diabetes Study (UKPDS) Group Glycemic control with diet, sulfonylurea, metfotmin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49) JAMA. 1999;281:2005–2012. doi: 10.1001/jama.281.21.2005. [DOI] [PubMed] [Google Scholar]
  • 6.Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin. 2007;23:945–952. doi: 10.1185/030079907x178766. [DOI] [PubMed] [Google Scholar]
  • 7.Hansen KB, Knop FK, Holst JJ, Vilsbøll T. Treatment of type 2 diabetes with glucagon-like peptide-1 receptot agonists. Int J Clin Pract. 2009;63:1154–1160. doi: 10.1111/j.1742-1241.2009.02086.x. [DOI] [PubMed] [Google Scholar]
  • 8.Goykhman S, Drincic A, Desmangles JC, Rendell M. Insulin glargine: A review 8 years after its introduction. Expert Opin Pharmacother. 2009;10:705–718. doi: 10.1517/14656560902775677. [DOI] [PubMed] [Google Scholar]
  • 9.Goldman-Levine JD, Lee KW. Insulin detemir—a new basal insulin analog. Ann Pharmacother. 2005;39:502–507. doi: 10.1345/aph.1E334. [DOI] [PubMed] [Google Scholar]
  • 10.Nauck MA, Heimesaat MM, Behle K. Effects of glucagon-like peptide 1 on counterregu-latory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87:1239–1246. doi: 10.1210/jcem.87.3.8355. [DOI] [PubMed] [Google Scholar]
  • 11.Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept. 2003;114:115–121. doi: 10.1016/s0167-0115(03)00111-3. [DOI] [PubMed] [Google Scholar]
  • 12.Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101:515–520. doi: 10.1172/JCI990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet. 2002;359:824–830. doi: 10.1016/S0140-6736(02)07952-7. [DOI] [PubMed] [Google Scholar]
  • 14.Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157. doi: 10.1053/j.gastro.2007.03.054. [DOI] [PubMed] [Google Scholar]
  • 15.Gallwitz B. Exenatide in type 2 diabetes: Treatment effects in clinical studies and animal study data. Int J Clin Pract. 2006;60:1654–1661. doi: 10.1111/j.1742-1241.2006.01196.x. [DOI] [PubMed] [Google Scholar]
  • 16.Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117:77–88. doi: 10.1016/j.regpep.2003.10.028. [DOI] [PubMed] [Google Scholar]
  • 17.Knudsen LB, Nielsen PF, Huusfeldt PO. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43:1664–1669. doi: 10.1021/jm9909645. [DOI] [PubMed] [Google Scholar]
  • 18.Wajcberg E, Tavaria A. Exenatide: Clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2009;10:135–142. doi: 10.1517/14656560802611832. [DOI] [PubMed] [Google Scholar]
  • 19.Neumiller JJ, Campbell RK. Liraglutide: A once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2009;43:1433–1444. doi: 10.1345/aph.1M134. [DOI] [PubMed] [Google Scholar]
  • 20.Matthews JE, Stewart MW, De Boever EH, Albiglutide Study Group Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagonlike peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:4810–4817. doi: 10.1210/jc.2008-1518. [DOI] [PubMed] [Google Scholar]
  • 21.Christensen M, Knop FK, Holst JJ, Vilsboll T. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs. 2009;12:503–513. [PubMed] [Google Scholar]
  • 22.Rettetstøl K. Taspoglutide: A long acting human glucagon-like polypeptide-1 analogue. Expert Opin Investig Drugs. 2009;18:1405–1411. doi: 10.1517/13543780903164205. [DOI] [PubMed] [Google Scholar]
  • 23.Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–553. doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  • 24.American Diabetes Association Standards of medical care in diabetes—2009. Diabetes Care. 2009;32(Suppl 1):S13–S61. doi: 10.2337/dc09-S013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2009. http://www.cochrane-handbook.org Version 5.0.2 [updated September 2009], Accessed June 22, 2010. [Google Scholar]
  • 26.Heine RJ, Van Gaal LF, Johns D, GWAA Study Group Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med. 2005;143:559–569. doi: 10.7326/0003-4819-143-8-200510180-00006. [DOI] [PubMed] [Google Scholar]
  • 27.Barnett AH, Butget J, Johns D. Tolerability and efficacy of exenatide and tittated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29:2333–2348. doi: 10.1016/j.clinthera.2007.11.006. [DOI] [PubMed] [Google Scholar]
  • 28.Bunck MC, Diamant M, Cotnér A. One-year treatment with exenatide improves beta-cell function, compated with insulin glargine, in metformin-treated type 2 diabetic patients: A randomized, controlled trial. Diabetes Care. 2009;32:762–768. doi: 10.2337/dc08-1797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Russell-Jones D, Vaag A, Schmitz O, Litaglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group Liraglutide vs insulin glatgine and placebo in combination with metfotmin and sulfonylurea thetapy in type 2 diabetes mellitus (LEAD-5 met+SU): A tandomised conrrolled trial. Diabetologia. 2009;52:2046–2055. doi: 10.1007/s00125-009-1472-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Davies MJ, Donnelly R, Barnett AH. Exenatide compated with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: Results of the Helping Evaluate Exenatide in patients with diabetes compated with Long-Acting insulin (HEELA) study. Diabetes Obes Metab. 2009;11:1153–1162. doi: 10.1111/j.1463-1326.2009.01154.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Secnik Boye K, Matza LS, Oglesby A. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes. 2006;4:80. doi: 10.1186/1477-7525-4-80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Mittendorf T, Smith-Palmer J, Timlin L. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: Cost-effectiveness analysis in the Getman setting. Diabetes Obes Metab. 2009;11:1068–1079. doi: 10.1111/j.1463-1326.2009.01099.x. [DOI] [PubMed] [Google Scholar]
  • 33.Brändie M, Erny-Albrecht KM, Goodall G. Exenatide versus insulin glargine: A cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther. 2009;47:501–515. doi: 10.5414/cpp47501. [DOI] [PubMed] [Google Scholar]
  • 34.Woehl A, Evans M, Tetlow AP, McEwan P. Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom. Cardiovasc Diabetol. 2008;7:24. doi: 10.1186/1475-2840-7-24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Ray JA, Boye KS, Yurgin N. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: A model of long-term clinical and cost outcomes. Curr Med Res Opin. 2007;23:609–622. doi: 10.1185/030079907X178685. [DOI] [PubMed] [Google Scholar]
  • 36.Amoti RE, Lau J, Pittas AG. Efficacy and safety of inctetin thetapy in type 2 diabetes: Systematic review and meta-analysis. JAMA. 2007;298:194–206. doi: 10.1001/jama.298.2.194. [DOI] [PubMed] [Google Scholar]
  • 37.Stratton IM, Adler AI, Neil HA. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405–412. doi: 10.1136/bmj.321.7258.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Cai J, Pajak A, Li Y. Total cholesterol and mottality in China, Poland, Russia, and the US. Ann Epidemiol. 2004;14:399–408. doi: 10.1016/j.annepidem.2003.10.012. [DOI] [PubMed] [Google Scholar]
  • 39.Lewington S, Clarke R, Qizilbash N, Prospective Studies Collaborarion Age-specific relevance of usual blood pressure to vasculat mottality: A meta-analysis of individual data fot one million adults in 61 prospective studies [published correction appears in Lancet. 2003;361:1060] Lancet. 2002;360:1903–1913. doi: 10.1016/s0140-6736(02)11911-8. [DOI] [PubMed] [Google Scholar]
  • 40.Williams B. The Hypertension in Diabetes Study (HDS): A catalyst for change. Diabet Med. 2008;25(Suppl 2):13–19. doi: 10.1111/j.1464-5491.2008.02506.x. [DOI] [PubMed] [Google Scholar]
  • 41.Hyperrension in Diabetes Study (HDS) I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens. 1993;11:309–317. doi: 10.1097/00004872-199303000-00012. [DOI] [PubMed] [Google Scholar]
  • 42.Hypertension in Diabetes Study (HDS) II. Incteased risk of catdiovasculat complications in hypettensive type 2 diabetic patients [published correction appeals in J Hypertens. 1993;11:681] J Hypertens. 1993;11:319–325. doi: 10.1097/00004872-199303000-00013. [DOI] [PubMed] [Google Scholar]
  • 43.Wilson PW, D’Agostino RB, Sullivan L. Overweight and obesity as detetminants of cardiovascular risk: The Framingham experience. Arch Intern Med. 2002;162:1867–1872. doi: 10.1001/archinte.162.16.1867. [DOI] [PubMed] [Google Scholar]
  • 44.Whitmote C. Type 2 diabetes and obesity in adults. Br J Nurs. 2010;19:880–886. doi: 10.12968/bjon.2010.19.14.49041. [DOI] [PubMed] [Google Scholar]
  • 45.Yusuf HR, Giles WH, Croft JB. Impact of multiple risk factor profiles on determining cardiovascular disease risk. Prev Med. 1998;27:1–9. doi: 10.1006/pmed.1997.0268. [DOI] [PubMed] [Google Scholar]
  • 46.Gerich JE. Postprandial hyperglycemia and cardiovascular disease. Endocr Pract. 2006;12(Suppl 1):47–51. doi: 10.4158/EP.12.S1.47. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES